Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia

Yangzhou No.1 People's Hospital

Status and phase: Completed; Phase 3

Conditions: Fasciculation

Treatments: Drug: Cisatracurium

Study type: Interventional

Funder types: Other

Identifiers

NCT02481193

YZYY-610

Details and patient eligibility

About

The purpose of this study is to investigate the effects of different doses of cisatracurium pretreatment on succinylcholine-induced fasciculations and postoperative myalgia.

Full description

Purpose: To investigate the effects of different doses of cisatracurium pretreatment on succinylcholine-induced fasciculations and postoperative myalgia.

Methods: Ninety patients scheduled for laparoscopic cholecystectomies were equally randomized into three groups to receive pretreatment of 0.005, 0.01, and 0.02 mg/kg cisatracurium, respectively. General anesthesia was induced 3.5 min later, train of four stimulation was monitored 4.5 min later, succinylcholine 1.5 mg/kg was injected 5 min later, and endotracheal intubation was implemented 6.5 min later. The side effects of cisatracurium, intensity of fasciculations, intubating conditions, time and extent to maximal depression of twitch and time for its recovery to 20% of control value, severity of myalgia at 24 h postoperatively, serum potassium before the induction, at the time of endotracheal intubation, and 5 min after intubation were recorded.

Enrollment: 90 patients

Sex: All

Ages: 20 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• American Standards Association (ASA) physical status I or II patients scheduled for elective laparoscopic cholecystectomies with tracheal intubation requiring general anesthesia
• 20 - 65 years old
• without acid-base imbalance and electrolyte disturbance
• with normal hepatic and renal function

Exclusion criteria

• Patients with known hyperkalemia
• Patients with increased intraocular pressure
• Patients with increased intracranial pressure
• Patients with symptoms of gastroesophageal reflux
• Patients with anticipated airway difficulties
• Patients with malignant fever
• Patients with neuromuscular disease
• Patients with burn or crush injuries
• Patients with taking drugs known to alter the action of neuromuscular blockers
• Patients with with a body mass index exceeding 30

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

90 participants in 3 patient groups

Cisatracurium 0.005 mg/kg

Experimental group

Description:

The group received pretreatment of cisatracurium 0.005 mg/kg.

Treatment:

Drug: Cisatracurium

Cisatracurium 0.01 mg/kg

Experimental group

Description:

The group received pretreatment of cisatracurium 0.01 mg/kg

Treatment:

Drug: Cisatracurium

Cisatracurium 0.02 mg/kg

Experimental group

Description:

The group received pretreatment of cisatracurium 0.02 mg/kg

Treatment:

Drug: Cisatracurium